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Background
C o m m u n i t yA d v i s o r yB o a r d s( C A B S )h a v ep l a y e da n
important role in ensuring community oversight of AIDS
vaccine trials and are an accepted part of the ethical con-
duct of AIDS vaccine trials. China’s political system limits
community engagement in trial communities and whole-
sale application of western CAB approaches does not
accomplish the intent of a CAB. We adapted the CAB
concept to China’s political system through a multi year
process of research and pilot testing in collaboration with
six provincial CDCs conducting AIDS prevention research
studies.
Methods
Using questionnaires developed by IAVI for a global
CABS study, we carried out an assessment of existing
CABS in six provinces in China. The questionnaire
examined membership, process, and governance along
with other aspects of CABS operations. The results were
used to revise standard CABS guidelines developed by
IAVI for use in Africa and India. The revised guidelines
were pilot tested in three sites, in Yunnan, Guangxi, and
Shanxi. In depth interviews were also conducted with
CAB members and local CDCS.
Results
A revised version of Chinese CABS guidelines was pub-
lished in October 2011 and publicized at China’sA I D S
Prevention Conference by China’s AIDS Ethical Review
Board and IAVI. The CABS guidelines are now being
promoted as part of the ethical requirements for AIDS
prevention clinical trial research by China’sN a t i o n a l
Center for AIDS Prevention and Control.
Conclusion
Developing and adapting ethical tools for ensuring com-
munity input and oversight of clinical trial research in
China is necessary given China’s political system. These
newly adapted CABS guidelines provide a mechanism to
accomplish the intention of a CAB even while different
in form and governance from standard CABS elsewhere.
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